Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
STOP-HER2
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
- NCT05721248 ↗
- Active, not recruiting
- Dana-Farber Cancer Institute
- Standard
We haven't built an HCP commentary report on STOP-HER2 (Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on STOP-HER2 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 11 | |
| X threads | 5 | |
| Podcasts | 2 |
The trial
ClinicalTrials.gov- Official title
- The STOP-HER2 Trial: A Phase 2 Study of Stopping Trastuzumab - Outcomes in Patients With HER2+ Metastatic Breast Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Breast Cancer; Metastatic Breast Cancer; HER2-positive Breast Cancer
- Interventions
- Cessation of anti-HER2 treatment
- Arms
- Cohort 1: Observational Continue Anti-HER2 Therapy · No intervention
- Cohort 2: - Stop Anti-HER2 Therapy · Experimental
- Enrollment
- 82
- Primary outcomes
- 1-year progression-free survival (PFS) Stopped Anti-HER2 Treatment
- 1-year progression-free survival (PFS) Continued Anti-HER2 Treatment
- Sponsor
- Dana-Farber Cancer Institute with National Cancer Institute (NCI), Gateway for Cancer Research, Susan G. Komen Breast Cancer Foundation, Translational Breast Cancer Research Consortium, Johns Hopkins University
- Start
- Apr 19, 2023
- Primary completion
- Jun 22, 2026
- Results posted
- No
- Registry record
- NCT05721248 · updated Aug 6, 2026